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Abstract 
It was shown that the indole derivate SS-68 (50 and 250 µg/kg intravenous) in acute experiments 
on cats with neurogenic atrial fibrillation (AF) has a dose-dependent antiarrhythmic action which 
is associated with the neurotropic influence of this substance, since the suppression of the AF 
coincides with its anticholinergic effect observed for more than 2 hours, but cardiotropic action at 
this time was not observed. High antiarrhythmic activity of SS-68 to neurogenic AF may be due 
to the IKAch inhibition and blockade of M2-cholinergic receptors. 
SS-68 (50 µg/kg intravenous) in experiments on rabbits is characterized by the following 
pharmacokinetic parameters: Cmax = 14.5 ng/ml of blood plasma (duration of plasma exposure of 
SS-68 is 4 hours), T1/2 = 1,1 ± 0.06 hours, MRT(0 – t) = 1.6 ± 0.08 hours, AUC(0 – 1440) = 1006.1 ± 
147.7 ng/ml×min, Vss = 4.8 ± 0.8 l/kg and CL = 0.051 l/h. 
Based on pharmacodynamic and pharmacokinetic parameters it was suggested that 
anticholinergic action of SS-68 in neurogenic AF will occur in a much lower dose than 50 mg/kg. 
Key words: vagus nerve, neurogenic atrial fibrillation, indole derivate SS-68, antiarrhythmic 
action, pharmacokinetics. 
Introduction 
Atrial fibrillation is the most common heart beat 
disorder. For the 50-year period of observation in the 
Framingham study, the morbidity of AF corrected to 
age increased fourfold [1]. From 1990 to 2010, the 
prevalence of AF in the world and associated with it 
morbidity and mortality, despite all efforts of medical 
science and health care increased twofold [2]. 
According to forecasts over the next 3 decades the 
number of patients with AF in Europe and the United 
States will increase by more than twofold, which is 
reason enough to call this arrhythmia "global 
epidemic" [3, 4, 5]. 
In recent years in the treatment of AF there is 
the preference for class III antiarrhythmic drugs 
(classification by E. M. Vaughan-Williams [6]), 
acting mainly at the expense of slowing 
repolarization and increasing the duration of 
refractory periods [7].  
Despite the fact that to the present time in our 
country and abroad there were created a number of 
different on the effectiveness and mechanism of 
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action of class III antiarrhythmic drugs (amiodarone, 
sotalol, bretylium, dofetilide, ibutilide, azimilide, 
vernakalant, dronedarone, nibentan, niferidil), search 
and development of representatives of this group of 
drugs continues, that is due to its not enough 
effectiveness and presence of side effects, the main of 
which is the torsades de pointes [7]. 
Experimental study of effectiveness and mode of 
action of new class III antiarrhythmic drugs is carried 
out using various models of auricular fluttering [8, 9]. 
Of these, greater attention should be a model of 
neurogenic AF [8, 10], simulating in healthy animals 
without prior myocardial damage by steam 
stimulation of the atria on the back of vagal 
asystolism, initiated by irritation of the vagus nerve. 
This model in comparison with the known analogues, 
in which different approaches are used to 
development and maintenance of AF [8, 11, 12, 13, 
14, 15], is not associated with artificial irregularities 
of the internal environment and is control that brings 
it the most to the pathogenesis of AF in clinical 
practice [16, 17]. Simulation of neurogenic AF made 
possible to study antifibrillatory action of many 
substances, including representatives of class III 
antiarrhythmic drugs [18, 19, 20, 21, 22, 23]. 
In previous studies it was shown that SS-68 on 
the mode of cardiotropic action may be fits into class 
III antiarrhythmic drugs [24]. It should be noted that 
in experiments on dogs SS-68 suppresses auricular 
fluttering [25], which is simulated by a mechanical 
destruction of the sinus node and subsequent 
electrical stimulation of the right atrium according to 
the method described by P. A. Galenko-Yaroshevskii 
et al. [8] A. Rosenblueth, G. Ramos [26]. 
Anticholinergic activity of SS-68 in the neurogenic 
AF has not been studied. In addition, the main 
pharmacokinetic parameters of the minimum 
effective doses of SS-68 have not been studied. 
The aim of this study was to study 
anticholinergic activity of SS-68 in the neurogenic 
AF and identify its main pharmacokinetic parameters 
in minimum anticholinergic dose. 
Experimental 
Experiments to study anticholinergic activity of 
SS-68 in neurogenic AF were performed on 16 cats 
weighing 2.6 to 3.4 kg with anesthesia by 
intraperitoneal administration of 1% of a mixture of 
α-chloralose and aethaminalum-natrium (75 and 
15 mg/kg, respectively) and artificial pulmonary 
ventilation according to the method developed by 
Y. R. Sheikh-Zade, P. A. Galenko-Yaroshevsky [10]. 
Neurogenic AF was simulated by application to 
the endocardium of the right atrium 2 electric pulses 
(5 ms, 4 threshold) with an interval of 40 ms on the 
back of rhythmic stimulation of the cervical portion 
of the right vagus nerve (2 ms, 40 Hz, 6 thresholds) 
using the electrostimulator ESU-2. ECG tracing 
(intra-atrial) was performed using beat-to-beat 
ratemeter on the recording meter H-338-2, while 
visual inspection of the events was conducted by 
using an 8-channel indicator IM 789. Agent SS-68 
was administered intravenous in doses of 50 and 
250 mg/kg. 
In the beginning of the experiment, and then 
after the administration of the SS-68 at 5, 30, 60 and 
120 minutes there were determined the duration of 
the intervals P-P and P-Q ECG, sinoatrial conduction 
time [27, 28], excitation thresholds of the atria and 
vagus nerve, atrial effective refractory period, the 
duration of AF, synchronizing and tonic components 
of the chronotropic effect of vagus nerve [8]. 
The research results were statistically analyzed. 
by the method of direct and indirect differences 
[29, 30] with the definition of arithmetic average 
(M), standard error of the mean (± m) and indices of 
statistical significance (p). The differences were 
considered significant at p < 0.05.  
The pharmacokinetics of SS-68 was studied on 
12 chinchilla rabbits, which were pre-catheterized in 
the right ear vein. 12 hours before the start of the 
experiment the animals were deprived of feed, 
leaving free access to water. The test substance was 
administered on the third day after catheterization 
intravenous bolus to 6 rabbits in the ear vein in the 
form of a solution of 500 µg/ml in water for injection 
at a dose of 50 mg/kg. Blood was sampled through a 
catheter in a volume of 0.3 ml in polypropylene tubes 
containing 20 µl of 5 % EDTA before administration 
and 5, 15, 30, 60, 120, 240, 480 and 1440 minutes 
after administration. Blood plasma was separated by 
centrifugation at 5600 g for 10 min and stored until 
analysis at -70 C. 
To determine the concentration there was used 
previously validated method for determining SS-68 
in the blood plasma of rabbits. Main pharmacokinetic 
parameters were calculated by A. A. Firsov et al. [31] 
in Microsoft Office Excel. Outliers in each time point 
were identified using a statistical test of Grubbs [32]. 
This test is well-proven in similar studies [33]. 
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Quantification of SS-68 in the blood plasma of 
rabbits was carried out on a liquid chromatograph LC 
UltiMate 3000 (Thermo Fisher Scientific, USA). 
Detection of analyte was performed on a mass 
spectrometer Velos Pro (Thermo Scientific, USA) 
with hot electrospray ionization (H-ESI-II). 
Chromatographic separation was performed on a 
column size 150 × 3.0 mm, filled by reversed-phase 
sorbent Zorbax Eclipce XDB C18 with particle size 
3.0 mm with protective column Zorbax Eclipce XDB 
C18 12.5×3.0 mm with a particle size of 5.0 µm at a 
temperature of 40◦C in the mode of linear gradient of 
eluant at a flow rate of 0.4 ml/min by the following 
program: 
Separation stage: Eluant A (5 mM Ammonium 
acetate + 0.1% formic acid) 55% → 45%; Eluant b 
(acetonitrile) 45% → 55% for 4 minutes; 
Washing stage: Eluant A (5 mM Ammonium 
acetate + 0.1% formic acid) 45%; Eluant b 
(acetonitrile) – 55% – 0,5 minutes; 
Trim stage: Eluant A (5 mM Ammonium acetate 
+ 0.1% formic acid) – 55%; Eluant b (acetonitrile) 
45% for 2 minutes. 
The volume of injected sample was 5 µl. 
Scanning was performed by selected-ion monitoring 
(SIM). The transition mass for SS-68 – 
305,26→208,0, internal standard (fabomotizole) – 
307,41→114,0. 
Results and evaluation 
SS-68 at a dose of 50 mg/kg at 5, 30, 60 and 120 
min after intravenous administration caused a 
statistically significant reduction in the duration of 
AF 85, 73, 50 and 33%, respectively. The intervals 
P-P and P-Q of ECG, the excitation threshold of the 
atrial effective refractory period and sinoatrial 
conduction of excitation were not be significantly 
changed. Against this background, SS-68 had 
vagolytic effect, manifested a significant increase in 
excitation thresholds of vagus nerve 16% (to the 5th 
min of the study), the synchronizing and tonic 
components of the chronotropic effect of vagus 
nerve, respectively, 50 and 47, 41 and 41, 41 and 37, 
37 and 31% (to the 5, 30, 60 and 120 th min of the 
study) (table 1). 
With increasing dose of SS-68 to 250 mg/kg at 
5, 30, 60 and 120 min was a statistically significant 
reduction in the duration of AF 92, 84, 62 and 54%, 
respectively. Intervals P-P and P-Q of ECG, as well 
as the effective refractory period was significantly 
increased, there were P-P 13, 10 and 8% (5, 30 and 
60th min), P-Q 22 and 14% (for 5 and 30 min) and 
effective refractory period 18, 13 and 12% (5, 30 and 
60th min of the study). Excitation thresholds of the 
atria and sinoatrial conduction of excitation remained 
virtually unchanged. Vagolytic activity of SS-68 was 
manifested in the significant increase of the 
excitation thresholds of vagus nerve 24% and 14% 
(for 5 and 30 min) and the inhibition of the tonic and 
synchronizing components of the chronotropic effect 
of this nerve 62 and 58, 60 and 52, 44 and 58, 56 and 
42%, respectively (to the 5, 30, 60 and 120 th min of 
the study) (table 2). 
It is known that increased tone of the 
parasympathetic nerves causes a reduction in the 
duration of AF of cardiomyocytes of the atria due to 
the acetylcholine-activated outgoing K
+
-current 
(IKAch) [34, 35]. It is shown that many class III 
antiarrhythmic drugs (sotalol, E-4031, MS-551, 
amiodarone, ambasilide, nibentan, niterider) have a 
preventive and neutralize effect against cholinergic 
AF, which is due to the inhibition of IKAch by 
blockade of M2-cholinergic receptors associated with 
IKAch by regulatory β – and γ-subunits of the 
G protein [34, 35], and/or directly IKAch channel 
[36, 37, 38]. 
In recent experiments on mammalian cardiac 
myocytes (whole cell mode using the method of 
patch-clamp [8, 39, 40]) there was found that the 
greatest sensitivity to SS-68 has IKAch, L-type Ca
2+
current ICaL and fast K
+
-current of the detained
straightening IKr (median effective concentration IC50 
of SS-68 = 1.28, 1.78 and 2.75 µm, respectively) and 
moderate sensitivity characteristic for ultra-rapid 
delayed-rectifier K
+
-current IKur and ATP-dependent
inwardly rectifying K
+
-current IKATP (IC50 of SS-68 =
19.8 and 20.0 µm, respectively), low sensitivity to 
transient outward potassium current Ito (IC50 of SS-
68 = 165.5 µm). Weakly susceptible to the action of 
SS-68 there were the fast Na
+
current INa, inward
rectifying K
+
-current IK1, and slow component a
current of the detained straightening IKs [24]. In 
addition, in experiments on preparations of the left 
atrium of the rat (with the registration of the action 
potential by the method of intracellular lead of 
bioelectrical activity [41]) there was shown that SS-
68 at a concentration of 10 µm (definition of 
minimum effective concentration was not conducted) 
weakens the effects of general stimulation of the M2 
– and M3-cholinergic receptors by pilocarpine (at
concentration of 10 µm) [42]. Since the decline in 
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SS-68 effect of stimulation of M3-cholinergic 
receptors may not be related to its effect on IKAch, 
because it is activated only by stimulation of M2 and 
M4 cholinergic receptors [43], the last of which in rat 
cardiomyocytes play a minor role, and M1-
cholinergic receptors are absent [44, 45, 46], we can 
assume that the antiarrhythmic effect of SS-68 on 
neurogenic AF is associated with its inhibitory effect 
on IKAch and blocking M2-cholinergic receptors. 
By the definition of the main pharmacokinetic 
parameters of SS-68 at a dose of 50 µg/kg has been 
established that its maximum concentration in plasma 
(Cmax) is 14.5 ng/ml; duration of content of SS-68 in 
the blood is 4 hours. The shape of the concentration 
time curve is biexponential, suggesting rapid first 
phase of distribution, alternating a slower phase of 
elimination. The presence of a plateau indicates a 
multi-phase distribution, which occur sequentially. 
Two hours of the study, the concentration of SS-68 
reduced 7.2 times (the second hour there was 
determined 2.0 ng/ml in blood plasma). It suggests 
that SS-68 in such dose rapidly eliminates in rabbits. 
Main pharmacokinetic parameters did not show high 
values of elimination half-life (T1/2 = 1.1 ± 0.06 
hours) and the middle residence time (MRT(0-t) = 1.6 
± 0.08 hours). Fast reduction of concentration in 
plasma causes a small value of the area under the 
curve (AUC(0-1440) = 1006.1 ± 147.7 ng/ml × min. The 
value of the stationary distribution volume (Vss) equal 
to 4.8+0.8 l/kg, that exceeds the amount of 
extracellular fluid in the body of rabbits, indicating a 
high ability of the drug to distribut and accumulate in 
the tissues. It is connected with the low value of 
systemic clearance (CL = 0.051 l/h).  
Thus, SS-68 in conditions of neurogenic AF, 
caused by the irritation of the vagus nerve in cats, has 
a dose-dependent antiarrhythmic effect that is 
associated with the pre-emptive neurotropic influence 
of this agent, since the neutralize of the AF coincides 
with its anticholinergic effect observed over 2 hours 
and cardiotropic action at this time is absent. High 
antiarrhythmic activity of SS-68 in neurogenic AF 
may be due to the inhibition of IKAch and blockade of 
M2-cholinergic receptors. It is not excluded that 
antiarrhythmic activity of SS-68 in neurogenic AF 
will manifest itself in lower doses. This is shown by 
the pharmacodynamic and pharmacokinetic 
parameters of SS-68. To confirm this assumption 
more researches of the influence of SS-68 in 
neurogenic AF in the lower dose range are needed. 
The method of synthesis of agent SS-68 
modified and the necessary quantity acquired as part 
of the state assignment of the Ministry of education 
and science of the Russian Federation No. 
4.129.2014/K at the Department of chemistry of 
natural and macromolecular compounds, faculty of 
chemistry of Southern Federal University. 
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Table 1 
The influence of SS-68 (50 µg/kg intravenous) on the cardiac output and the duration of AF when irritation of the vagus nerve in cats (M ± m, n = 8) 
The indicators and their 
dimension 
Source 
values
Duration of the action, min 
5 30 60 120 
Baseline duration of the Р-Р interval of 
ECG, msec 
388.0 ± 14.0 376.0 ± 13.0 
[97.0] 
387.0 ± 14.0 
[100.0] 
384.0 ± 15.0 
[99.0] 
385.0 ± 15.0 
[99.0] 
Excitation threshold of atria, mV 438.0 ± 60.0 476.0 ± 90.0 
[109.0] 
458.0 ± 80.0 
[105.0] 
402.0 ± 70.0 
[92.0] 
415.0 ± 60.0 
[95.0] 
Effective refractory period of a 
myocard, msec 
142.0 ± 8.0 138.0 ± 6.0 
[97.0] 
135.0 ± 8.0 
[95.0] 
140.0 ± 6.0 
[100.0] 
139.0 ± 5.0 
[90.0] 
Sinoatrial conduction of excitation. 
msec 
28.0 ± 3.0 26.0 ± 2.0 
[93.0] 
29.0 ± 3.0 
[104.0] 
27.0 ± 2.0 
[96.0] 
25.0 ± 2.0 
[89.0] 
P-Q interval of ECG, msec 75.0 ± 4.0 73.0 ± 2.0 
[97.0] 
76.0 ± 3.0 
[101.0] 
74.0 ± 2.0 
[99.0] 
77.0 ± 4.0 
[103.0] 
Excitation thresholds of vagus nerve, 
mV 
380.0 ± 40.0 440.0 ± 20.0* 
[116.0] 
410.0 ± 50.0 
[108.0] 
400.0 ± 40.0 
[105.0] 
410.0 ± 50.0 
[108.0] 
Synchronizing component of the 
chronotropic effect of vagus nerve, 
msec 
259.0 ± 28.0 130.0 ± 10.0* 
[50.0] 
153.0 ± 24.0* 
[59.0] 
154.0 ± 20.0* 
[59.0] 
162.0 ± 25.0* 
[63.0] 
Tonic component of the chronotropic 
effect of vagus nerve, msec 
98.0 ± 12.0 52.0 ± 5.0* 
[53.0] 
58.0 ± 12.0* 
[59.0] 
62.0 ± 14.0* 
[63.0] 
68.0 ± 10.0* 
[69.0] 
Duration of AF, sec 140.0 ± 7.0 21.0 ± 4.0* 
[15.0] 
38.0 ± 6.0* 
[27.0] 
70.0 ± 12.0* 
[50.0] 
94.0 ± 14.0* 
[67.0] 
Comment: Here and in table 2: in brackets there are the indicators expressed in %; *p < 0.05 in comparison with baseline data. 
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Table 2 
The influence of SS-68 (250 µg/kg intravenous) on the cardiac output and the duration of AF when irritation of the vagus nerve in cats (M ± m, n = 8) 
The indicators and their 
dimension 
Source 
values 
Duration of the action, min 
5 30 60 120 
Baseline duration of the Р-Р interval of 
ECG, msec  
352.0 ± 8.0 398.0 ± 9.0* 
[113] 
387.0 ± 6.0* 
[110.0] 
379.0 ± 6.0* 
[108.0] 
360.0 ± 13 
[102.0] 
Excitation threshold of atria, mV 540.0 ± 60.0 560.0 ± 70.0* 
[117.0] 
560.0 ± 80.0 
[104.0] 
530.0 ± 50.0 
[98.0] 
520.0 ± 60.0 
[96.0] 
Effective refractory period of a 
myocard, msec 
136.0 ± 5.0 160.0 ± 4.0 
[104.0] 
150.0 ± 5.0 
[102.0] 
152.0 ± 4.0* 
[112.0] 
144.0 ± 9.0 
[106.0] 
Sinoatrial conduction of excitation. 
msec 
22.0 ± 2.0 22.0 ± 2.0 
[100.0] 
22.0 ± 2.0 
[100.0] 
21.0 ± 1.0 
[95.0] 
20.0 ± 2.0 
[91.0] 
P-Q interval of ECG, msec 72.0 ± 2.0 88.0 ± 2.0* 
[122.0] 
82.0 ± 3.0* 
[114.0] 
73.0 ± 3.0 
[101.0] 
70.0 ± 3.0 
[97.0] 
Excitation thresholds of vagus nerve, 
mV 
370.0 ± 40.0 460.0 ± 30.0* 
[124.0] 
420.0 ± 30.0* 
[114.0] 
390.0 ± 40.0 
[105.0] 
380.0 ± 30.0 
[103.0] 
Synchronizing component of the 
chronotropic effect of vagus nerve, 
msec 
265.0 ± 22.0 101.0 ± 28.0* 
[38.0] 
106.0 ± 23.0* 
[40.0] 
111.0 ± 22.0* 
[42.0] 
117.0 ± 23.0* 
[44.0] 
Tonic component of the chronotropic 
effect of vagus nerve, msec 
94.0 ± 12.0 39.0 ± 6.0* 
[42.0] 
45.0 ± 12.0* 
[48.0] 
53.0 ± 14.0* 
[56.0] 
55.0 ± 13.0* 
[58.0] 
Duration of AF, sec 15.0 ± 8.0 12.0 ± 4.0* 
[8.0] 
24.0 ± 5.0* 
[16.0] 
58.0 ± 6.0* 
[38.0] 
7.0. ± 6.0* 
[46.0] 
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